NanoViricides Develops First-In-Class Broad-Spectrum Antiviral Agent NV-387

Novel Host-Mimetic, Virus Killing Technology Platform

NanoViricides, Inc., a clinical-stage leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class, broad-spectrum antiviral agent. This innovative drug employs host-mimetic technology, designed to mimic the host's cell surface to attract and dismantle virus particles, offering a revolutionary approach to treating viral infections such as RSV, COVID-19, and influenza.

Resistance is Futile: Host-Mimetic Technology

NV-387's technology addresses the challenge of virus escape by using the same "landing sites" viruses use to infect cells. This approach ensures effectiveness even as viruses mutate, as the host's landing sites remain unchanged. This contrasts with vaccines and antibodies, which can lose effectiveness as viruses evolve.

Broad Antiviral Spectrum

NV-387 targets over 90% of human pathogenic viruses that use Sulfated Proteoglycans (SPG) as landing sites. Its design to mimic SPG allows it to attack a wide range of viruses, demonstrating strong antiviral activity in animal studies against various virus families, including coronaviruses and influenza viruses.

Superior Efficacy

In studies, NV-387 has shown superior efficacy to existing treatments like remdesivir for COVID-19 and Tamiflu for influenza. It has also demonstrated potential in treating RSV, a virus for which there is currently no cure, and has shown promise against novel viruses that may emerge in the future.

Safety Profile

NV-387 has successfully completed Phase I human clinical trials with no adverse events reported, indicating a strong safety profile. The drug's design and components have been carefully chosen to ensure safety, supported by studies showing no mutagenic, genotoxic, or immunogenic effects.

Future Prospects

NanoViricides is preparing NV-387 for Phase II clinical trials, aiming for regulatory approvals worldwide. The company believes NV-387 could be as revolutionary in antiviral treatment as penicillin was in antibacterial therapy, offering a single drug solution for a wide range of viral infections.

About NanoViricides

NanoViricides, Inc. is focused on developing nanomedicines for antiviral therapy, with NV-387 as its lead drug candidate. The company's technology is based on mimicking host-side features to prevent virus escape, offering a promising approach to treating and preventing viral diseases.